The Medicinal Chemistry and Lead Development Core (MCLDC) is a key component of the Antiviral Drug Discovery and Development Center, contributing to the goals of each of the individual projects. The MCLDC will provide hit-to-lead analysis, synthetic chemistry, structure-activity relationship (SAR) data and analysis, computational support, and lead optimization chemistry to further the CETR's goal of developing new replication inhibitors and other broad-based therapeutics for the treatment of emerging pathogens. In this role, the MCLDC, in conjunction with the Screening Core (SC), will be the central focus of the translational research component of the program. As the SC optimizes the novel assays developed by various Research Projects, and subsequently prosecutes the screening campaign, it will be the function of the MCLDC to assess the quality ofthe hit compounds that emerge, and ultimately to convert novel, tractable hits into potential clinically useful drugs with optimized biological and biophysical properties. As such, the MCLDC will work closely with both the SC and each of the Research Project teams. As new chemical entities are prepared during the lead optimization process, because of the anticipated synthetic throughput the SC will generally test these analogs in a primary assay in order to drive the SAR investigation. As described in detail below, appropriate compounds will also be provided to the various Research Project teams for advanced studies including efficacy, mechanism of action, and other experiments. The resulting data about these compounds, generated by the SC and Research Projects, will then be analyzed by the MCLDC in order to drive the iterative drug discovery program to completion. The MCLDC will incorporate key members of the SC and Research Project teams into the prioritization and decision making procedures. The end result of this process will be the identification of novel drugs appropriate for IND applications.
To combat novel emerging infections, drug resistant organisms, and potential weaponized biological threats, the identification of new therapeutic targets, and the development of drugs exploiting those targets, is essential. The overarching goal of this Core is to translate the discovery and validation of new therapeutic targets identified by the Research Projects into drugs by utilizing the data provided by the Screening Core, through synthetic and computational medicinal chemistry optimizatonn.
|Carpentier, Kathryn S; Morrison, Thomas E (2018) Innate immune control of alphavirus infection. Curr Opin Virol 28:53-60|
|McCarthy, Mary K; Davenport, Bennett J; Reynoso, Glennys V et al. (2018) Chikungunya virus impairs draining lymph node function by inhibiting HEV-mediated lymphocyte recruitment. JCI Insight 3:|
|Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein et al. (2018) Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. Viruses 10:|
|Johnson, Britney; VanBlargan, Laura A; Xu, Wei et al. (2018) Human IFIT3 Modulates IFIT1 RNA Binding Specificity and Protein Stability. Immunity 48:487-499.e5|
|Agostini, Maria L; Andres, Erica L; Sims, Amy C et al. (2018) Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio 9:|
|Pryke, Kara M; Abraham, Jinu; Sali, Tina M et al. (2017) A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. MBio 8:|
|McCarthy, Mary K; Morrison, Thomas E (2017) Persistent RNA virus infections: do PAMPS drive chronic disease? Curr Opin Virol 23:8-15|
|Sheahan, Timothy P; Sims, Amy C; Graham, Rachel L et al. (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:|
|Jones, Jennifer E; Long, Kristin M; Whitmore, Alan C et al. (2017) Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology. MBio 8:|
|Haese, Nicole N; Broeckel, Rebecca M; Hawman, David W et al. (2016) Animal Models of Chikungunya Virus Infection and Disease. J Infect Dis 214:S482-S487|
Showing the most recent 10 out of 24 publications